SRSS 021

Drug Profile

SRSS 021

Latest Information Update: 15 Apr 2004

Price : $50

At a glance

  • Originator Sirus
  • Class Antiemetics
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Nausea and vomiting

Most Recent Events

  • 15 Apr 2004 Discontinued - Preclinical for Emesis in United Kingdom (Sublingual)
  • 30 Jun 2003 Preclinical trials in Emesis in United Kingdom (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top